Ocular Therapeutix Inc. (NASDAQ:OCUL) is taking a hit, with shares plummeting over 25% during premarket trading after the much-anticipated data on their Axpaxli treatment for wet age-related macular degeneration (AMD) missed investor expectations. Traders had set their sights high, but the results didn’t deliver, sparking concerns about the drug’s commercial viability in a market that already has established players.
Axpaxli Trial Data: Promising Yet Disappointing
The Phase 3 SOL-1 superiority trial of Axpaxli was supposed to be a game-changer. Topline results showed that 74.1% of subjects treated with Axpaxli maintained vision at Week 36 compared to 65.9% for Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) Eylea (aflibercept). A notable risk difference of 17.5% sounds impressive until you factor in what the market wanted—something much bigger and bolder to compete effectively against well-established alternatives.
The numbers initially looked solid; however, when traders dug deeper into the findings, they realized that the durability advantage over Eylea was smaller than anticipated—a major red flag in a field where established therapies dominate and patient loyalty runs deep.
Durability Assessment Raises Eyebrows
A key focus of the trial was durability, which Ocular touted as a strong point for Axpaxli. While maintaining vision at Week 52 showed 65.9% in the Axpaxli arm versus just 44.2% for aflibercept—a risk difference of over 21%—it still fell short of being an outright game-changer that would capture significant market share from competitors like REGN's Eylea.
“Traders had hoped for numbers that would rock the boat; instead, they got just ripples.”
The Road Ahead: Regulatory Hurdles Loom
Ocular plans to submit a New Drug Application (NDA), contingent on discussions with the U. S. FDA—but will these numbers cut it? The upcoming SOL-R Phase 3 non-inferiority trial remains on track with topline data expected early in 2027, leaving many asking whether this will be too little too late given current sentiment around OCUL stocks.
